Enliven Therapeutics, Inc. Common Stock (ELVN) is a publicly traded Healthcare sector company. As of September 21, 2026, ELVN trades at $48.45 with a market cap of $3.62B and a P/E ratio of -26.48. ELVN moved -1.19% today. Year to date, ELVN is +217.34%; over the trailing twelve months it is +157.75%. Its 52-week range spans $13.30 to $62.32. Analyst consensus is strong buy with an average price target of $73.90. Rallies surfaces ELVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ELVN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ELVN recently traded at $48.45. Market cap is $3.62B. P/E ratio is -26.48. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $48.45 |
| Market Cap | $3.62B |
| P/E Ratio | -26.48 |
| EPS | $-1.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.32 |
| 52-Week Low | $13.30 |
| Volume | 635.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-103.69M |
| Gross Margin | 0.00% |
12 analysts cover ELVN: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $73.90.